Skip to main content
. 2019 Jun 12;10:2566. doi: 10.1038/s41467-019-10296-9

Table 3.

Myotoxicity and inflammation

Formulation Dose of polymer (mg) Dose of TTX (µg) Myotoxicity score (range)
Day 4
Myotoxicity score (range)
Day 14
Inflammation score (range)
Day 4
Inflammation score (range)
Day 14
Free TTXa 3.0 0 (0–1.0) 0 (0–1.0) 0 (0–1.0) 0 (0–1.0)
PEG200 562b 3.0 0 (0–1.0) 0 (0–1.0) 0 (0–1.0) 1.0 (0–1.0)
p Value 1.000 1.000 1.000 0.456
TgD8–TTXH 50c 80.0 1.0 (0–1.0) 1.0 (0–1.0) 1.0 (0–1.0) 1.0 (0–1.0)
p Value 0.456 0.456 0.456 0.456
TgD1–TTX 12.5c 31.9 1.0 (0–1.0) 1.0 (0–1.0) 0 (0–1.0) 1.0 (0–1.0)
p Value 0.456 1.000 1.000 0.456
TgD8P200–TTX 32.5c 10.0 0 (0–1.0) 0 (0–1.0) 1.0 (0–1.0) 0 (0–1.0)
p Value 1.000 0.456 0.456 1.000
TgD8P1000–TTX 25c 6.9 0 (0-0) 0.5 (0–1.0) 0.5 (0–1.0) 0.5 (0–1.0)
p Value 0.414 0.738 0.738 0.738
TgD8P2000–TTX 25c 3.5 0.5 (0–1.0) 0 (0–0) 0.5 (0–1.0) 0.5 (0–1.0)
p Value 0.738 0.182 0.738 0.738

Data are medians with interquartile ranges. P values are for the comparison of the tissue reaction of test compounds to that of free TTX. n = 3 per experimental group. Inflammation scores range: 0–4; myotoxicity scores range: 0–6

a3 µg of free TTX in 0.5 mL of PBS

b3 µg of free TTX in 0.5 mL of PEG200

cTD–TTX and TDP–TTX conjugates were formulated in 0.5 mL of PEG200